The MarketWatch News Department was not involved in the creation of this content. TEANECK, N.J., July 16, 2025 /PRNewswire/ -- GC Biopharma USA, Inc., a leader in plasma-derived products, announced ...
Today Kedrion Biopharma announced the nationwide commercial availability of QIVIGY, its FDA‑approved 10% Intravenous ...
Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat autoimmune conditions. With origins dating back to the 1950s, IVIG is currently ...
Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat autoimmune conditions. With origins dating back to the 1950s, IVIG is currently ...
DALLAS--(BUSINESS WIRE)--Advanced Infusion Care (AIC), a division of AIS Healthcare, today announced its participation in the Immunoglobulin National Society (IgNS) 12 th National Conference, which ...
Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat autoimmune conditions. With origins dating back to the 1950s, IVIG is currently ...
NEW YORK (Reuters Health) - Intravenous immunoglobulin (IVIg) may offer some relief for patients with sensorimotor neuropathy or nonataxic sensory neuropathy associated with primary Sjögren's syndrome ...
ARLINGTON, Texas--(BUSINESS WIRE)--AOM Infusion (“AOM”), a leading provider of specialty infusion and pharmacy services for chronic and complex conditions, has been selected by Kedrion Biopharma as a ...
"[O]ur study, which has the largest cohort to date, did not show an increased rate of VTEs in patients with DM on IVIG. Therefore, it is safe to start patients on this medicine as it is one of our ...
The prescribed dosage for Hizentra (immune globulin subcutaneous [human]) may vary depending on an individual’s treatment plan. Other factors, including your specific diagnosis, body weight, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results